The Clinical Laboratory’s Role in Addressing the Fentanyl Crisis
Stephanie Noblit, Esq. | July 10, 2024 | LAPPA
Presentations
Overview of Deflection, Drug Courts, and MAT in Correctional Settings
Stephanie Noblit, Esq. | June 8, 2024 | LAPPA
Over the Counter Naloxone and the Puzzle of Overdose Reversal
Jon Woodruff, Esq., Marta Sokolowska, PhD (FDA) & Yngvild Olsen, MD (SAMHSA) | June 8, 2024 | LAPPA
The Collateral Consequences of Drug Convictions and LAPPA’s Model Act
Heather Gray, Esq. & Joey Longley, JD (O’Neill Institute) | April 2, 2024 | LAPPA
Overview of OFR Model Law and Implementation
Stephanie Noblit, Esq. | March 6, 2024 | LAPPA
State of the States: A Legislative Roadmap for Reducing Overdose Deaths and Increasing Access to Treatment
Jon Woodruff, Esq. & Joseph Maschman, Esq | February 27, 2024 | LAPPA
Intro. to Information Sharing and Resources for OFRs
Jon Woodruff, Esq. | November 15, 2023 | LAPPA
Risks and Legal Liabilities of Deflection
Jon Woodruff, Esq. | September 14, 2023 | LAPPA
Expanding Naloxone Access in Policy and Practice: FDA Action and State Legislation
Jon Woodruff, Esq. | August 30, 2023 | LAPPA
Syringe Services Programs: How Comprehensive Programs Can Change Lives
Heather Gray, Esq. | August 30, 2023 | LAPPA
Introduction to Information Sharing and Resources
Jon Woodruff, Esq. | July 18, 2023 | LAPPA
Sustainability Efforts: Substance Use Model Legislation
Jon Woodruff, Esq. | June 16, 2023 | LAPPA
Nonprescription Naloxone: Update and Implications
Stephanie Noblit, Esq., MLS (ASCP)CM | June 3, 2023 | LAPPA
Nonprescription Naloxone: Update and Implications
Jon Woodruff | May 18, 2023 | LAPPA
Drug Checking Legislation and Advocacy
Jon Woodruff, Esq. | May 10, 2023 | LAPPA
Recovery Friendly Workplaces Model Act
Heather V. Gray, Esq. | March 22, 2023 | LAPPA
To Share or Not to Share
Jon Woodruff, Esq. | March 10, 2023 | LAPPA
Addressing Privacy and Confidentiality in Deflection While Managing Risk and Legal Liability
Jon Woodruff, Esq. | November 4, 2022 | LAPPA